1 Diagnostic and prognostic value of hematological and

2 immunological markers in COVID-19 infection: A meta-

3 analysis of 6320 patients

- 4 Rami M. Elshazli¹, Eman A Toraih^{2,3}, Abdelaziz Elgaml^{4,5}, Mohammed El-Mowafy⁴, Mohamed
- 5 El-Mesery⁶, Mohamed Nasreldien Amin⁶, Mohammad H Hussein², Mary T. Killackey⁷, Manal S
- 6 Fawzy ^{8*}, Emad Kandil ^{9*}
- 7 Department of Biochemistry and Molecular Genetics, Faculty of Physical Therapy, Horus
- 8 University Egypt, New Damietta, 34517, Egypt.
- ² Department of Surgery, Tulane University, School of Medicine, New Orleans, Louisiana, USA
- ³ Genetics Unit, Department of Histology and Cell Biology, Faculty of Medicine, Suez Canal
- 11 University, Ismailia, Egypt
- ⁴ Department of Microbiology and Immunology, Faculty of Pharmacy, Mansoura University,
- 13 Mansoura 35516, Egypt.
- ⁵ Department of Microbiology, Faculty of Pharmacy, Horus University Egypt, New Damietta,
- 15 *34517*, *Egypt*.
- ⁶ Department of Biochemistry, Faculty of Pharmacy, Mansoura University, Mansoura 35516,
- 17 *Egypt*.
- ⁷Tulane Transplant Institute, Tulane University, School of Medicine, New Orleans, LA, USA
- 19 ⁸ Department of Medical Biochemistry, Faculty of Medicine, Suez Canal University, Ismailia,
- 20 Egypt

- ⁹Division of Endocrine and Oncologic Surgery, Department of Surgery, Tulane University,
- 22 School of Medicine, New Orleans, LA, USA
- 24 *Correspondence authors
- 25 Email: <u>ekandil@tulane.edu</u> (EK)
- 26 Email: <u>manal_mohamed@med.suez.edu.eg</u> (MSF)
- 27 **Short Title:** COVID-19 infection and laboratory markers

Abstract

28

29

31

32

33

34

36

37

38

39

40

41

42

43

44

46

Objective

30 Evidence-based characterization of the diagnostic and prognostic value of the

hematological and immunological markers related to the epidemic of Coronavirus

Disease 2019 (COVID-19) is critical to understand the clinical course of the

infection and to assess in development and validation of biomarkers.

Methods

Based on systematic search in Web of Science, PubMed, Scopus, and Science

Direct up to April 22, 2020, a total of 52 eligible articles with 6,320 laboratory-

confirmed COVID-19 cohorts were included. Pairwise comparison between severe

versus mild disease, Intensive Care Unit (ICU) versus general ward admission, and

expired versus survivors were performed for 36 laboratory parameters. The pooled

standardized mean difference (SMD) and 95% confidence intervals (CI) were

calculated using the DerSimonian Laird method/random effects model and

converted to Odds ratio (OR). The decision tree algorithm was employed to

identify the key risk factor(s) attributed to severe COVID-19 disease.

Results

Cohorts with elevated levels of white blood cells (WBCs) (OR=1.75), neutrophil

count (OR=2.62), D-dimer (OR=3.97), prolonged prothrombin time (PT)

47 (OR=1.82), fibrinogen (OR=3.14), erythrocyte sedimentation rate (OR=1.60),

procalcitonin (OR=4.76), IL-6 (OR=2.10), and IL-10 (OR=4.93) had higher odds 48 of progression to severe phenotype. Decision tree model (sensitivity=100%, 49 specificity=81%) showed the high performance of neutrophil count at a cut-off 50 value of more than $3.74 \square \times 10^9 / L$ for identifying patients at high risk of severe 51 COVID 19. Likewise, ICU admission was associated with higher levels of WBCs 52 (OR=5.21), neutrophils (OR=6.25), D-dimer (OR=4.19), and prolonged PT 53 (OR=2.18). Patients with high IL-6 (OR=13.87), CRP (OR=7.09), D-dimer 54 (OR=6.36), and neutrophils (OR=6.25) had the highest likelihood of mortality. 55 **Conclusions** 56 Several hematological and immunological markers, in particular neutrophilic 57 count, could be helpful to be included within the routine panel for COVID-19 58 infection evaluation to ensure risk stratification and effective management. 59 60 Keywords: COVID-19; laboratory markers; mortality; prognosis; SARS-CoV-2 61 62 63 **Short Title:** COVID-19 infection and laboratory markers 64 65 66

Introduction

68

69

70

71

72

73

74

75

76

77

78

79

80

81

82

83

84

85

86

87

Coronavirus disease - 2019 (COVID-19) is a disease that was detected in December 2019 in Wuhan, China, and led to the risk of mortality of about 2% [1]. This disease is caused due to infection with a recently arising zoonotic virus known as the Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) [2]. Previously, infection with coronaviruses appeared in 2002 within China in the form of SARS-CoV, and it appeared later also in 2012 within Saudi Arabia that was known as Middle East Respiratory Syndrome (MERS-CoV) [3, 4]. All these coronaviruses are enveloped positive-strand RNA viruses that are isolated from bats that can be transferred from animals to humans, human to human, and animals to animals [5]. They share a similarity in the clinical symptoms in addition to specific differences that have been recently observed [5-7]. The symptoms of this disease appear with different degrees that start in the first seven days with mild symptoms such as fever, cough, shortness of breath, and fatigue [8]. Afterward, critical symptoms may develop in some patients involving dyspnea and pneumonia that require patient's management in intensive care units to avoid the serious respiratory complications that may lead to death [9]. However, there are no specific symptoms to diagnose coronavirus infection, and accurate testing depends on the detection of the viral genome using the reverse transcription-polymerase chain reaction (RT-PCR) analysis [10].

Unfortunately, COVID-19 is not limited to its country of origin, but it has spread all over the world. Therefore, there is no wonder emerging research has been directed to provide information and clinical data of patients infected with this virus that may help to not only to the early detection in different patient categories, but it will also help in the characterization of the viral complications with other chronic diseases [1, 2, 6, 9]. However, there is no sufficient data that characterize the changes in the hematological and immunological parameters in COVID-19 patients. In the current comprehensive meta-analysis study, we aimed to analyze different hematological, inflammatory, and immunological markers in COVID-19 patients at different clinical stages in different countries that may help in the early detection of COVID-19 infection and to discriminate between severity status of the disease to decrease the death risk.

Materials and Methods

Search strategy

This current meta-analysis was carried out according to the Preferred Reporting Items for Systematic reviews and Meta-analysis (PRISMA) statement [11] (**Table S1**). Relevant literature was retrieved from Web of Science, PubMed, Scopus, and Science Direct search engines up to April 22, 2020. Our search strategy included the following terms: "Novel coronavirus 2019", "2019 nCoV", "COVID-19",

"Wuhan coronavirus," "Wuhan pneumonia," or "SARS-CoV-2". Besides, we manually screened out the relevant potential article in the references selected. The above process was performed independently by three participants.

Study selection

107

108

109

110

111

112

113

114

115

116

117

118

119

120

121

122

123

124

125

126

No time or language restriction was applied. Inclusion criteria were as follows: (1) Types of Studies: retrospective, prospective, observational, descriptive or case control studies reporting laboratory features of COVID-19 patients; (2) Subjects: diagnosed patients with COVID-19 (3) Exposure intervention: COVID-19 patients diagnosed with Real Time-Polymerase Chain Reaction, radiological imaging, or both; with hematological testing included: complete blood picture (white blood cells, neutrophil count, lymphocyte count, monocyte count, eosinophils count, basophils, red blood cells, hemoglobin, hematocrit, and platelet count), coagulation profile (prothrombin time, international normalized ratio, activated partial thromboplastin time, thrombin time, fibrinogen, and D-dimer) or immunological parameters including inflammatory markers (ferritin, erythrocyte sedimentation rate, procalcitonin, and C-reactive protein), immunoglobulins (IgA, IgG, and IgM), complement tests (C3 and C4), interleukins (IL-4, IL-6, IL-8, IL-10, IL-2R, and TNF-α), and immune cells (B lymphocytes, T lymphocytes, CD4⁺ T cells, and CD8⁺ T cells); and (4) Outcome indicator: the mean and standard deviation or median and interquartile range for each laboratory test. The following exclusion

criteria were considered: (1) Case reports, reviews, editorial materials, conference abstracts, summaries of discussions, (2) Insufficient reported data information; or (3) *In vitro* or *in vivo* studies.

Data abstraction

Four investigators separately conducted literature screening, data extraction, and literature quality evaluation, and any differences were resolved through another two reviewers. Information extracted from eligible articles in a predesigned form in excel, including the last name of the first author, date and year of publication, journal name, study design, country of the population, sample size, and quality assessment.

Quality assessment

A modified version of the Newcastle-Ottawa scale (NOS) was adopted to evaluate the process in terms of queue selection, comparability of queues, and evaluation of results [12, 13]. The quality of the included studies was assessed independently by three reviewers, and disagreements were resolved by the process described above. Higher NOS scores showed a higher literature quality. NOS scores of at least six were considered high-quality literature.

Statistical analysis

146

147

148

149

150

151

152

153

154

155

156

157

158

159

160

161

162

163

164

performed using OpenMeta[Analyst] All analysis was [14] and comprehensive meta-analysis software version 3.0 [15]. First, a single-arm meta analysis for laboratory tests was performed. The standardized mean difference (SMD) and 95% confidence intervals (CI) were used to estimate pooled results from studies. Medians and interquartile range were converted to mean and standard deviation (SD) using the following formulas: [Mean=(Q1+median+Q3)/3] and [SD=IQR/1.35], whereas, values reported in the articles as mean and 95%CI were estimated using the following formula [SD= \sqrt{N} * (Upper limit of CI – Lower limit of CI)/3.92]. A continuous random-effect model was applied using the DerSimonian-Laird (inverse variance) method [16, 17]. Next, in the presence of individual patient data, single-armed observed values were converted to two-armed data to act as each other's control group based on covariate information. Only studies investigating different outcomes were considered as potential matched pairs, and two-arm meta-analysis was applied to compare between mild versus severe COVID-19 infection (based on the results of the chest radiography, clinical examination, and symptoms), ICU admission versus general ward admission, and expired versus survivors. Meta-analysis for each outcome was processed using a random-effects model since heterogeneity among studies was expected. For severity pairwise comparison, estimates of SMD served as quantitative measures of the strength of evidence against the null hypothesis of no difference in the population between mild and severe COVID-19 manifestations. SMD of <0.2, 0.2-0.8, and >0.8 indicated mild, moderate, and severe strength. For ICU admission and survival analysis, overall effect size estimates in SMD were then converted to the odds ratio (OR) with 95%CI for better interpretation by clinical domains.

Decision tree to identify predictors for poor outcomes

Using laboratory features for clinical prediction, the decision tree algorithm was employed to identify the key risk factors attributed to severe COVID-19 infection. The accuracy of the model was measured by the Area Under the Receiver Operating Characteristic (ROC) Curve (AUC), which depicts the true positive rate versus the false positive rate at various discrimination thresholds. The markers that have the highest AUC were identified, and the sensitivity and specificity of the cut-off threshold level were determined. R Studio was employed using the following packages: *tidyverse*, *magrittr*, *rpart*, *caret*, and *pROC*.

Trial sequential analysis (TSA)

The statistical trustworthiness of this meta-analysis assessment was conducted using TSA through combining the cumulative sample sizes of all appropriate records with the threshold of statistical impact to diminish the accidental errors and enhance the intensity of expectations [18]. Two side trials with "type I error (α)"

along with power set at 5% and 80% were employed. In the case of the "Z-curve" traverses the TSA monitoring boundaries, a reasonable degree of impact was accomplished, and no supplementary trials are crucial. Nevertheless, in case of the "Z-curve" failed to achieve the boundary limits, the estimated information size has not accomplished the required threshold to attract appropriate decisions and advance trials are mandatory. TSA platform (version 0.9.5.10 beta) was operated in the experiment.

Assessment of heterogeneity and publication bias

After that, the heterogeneity was evaluated using Cochran's Q statistic and quantified by using I^2 statistics, which represents an estimation of the total variation across studies beyond chance. Articles were considered to have significant heterogeneity between studies when the p-value less than 0.1 or I^2 greater than 50%. Subgroup analysis was performed based on the study sample size (\leq 50 patients compared to >50 patients) and the origin of patients (Wuhan city versus others). In addition, sensitivity analyses and meta-regression with the random-effects model using restricted maximum likelihood algorithm were conducted to explore potential sources of heterogeneity. Finally, publication bias was assessed using a funnel plot and quantified using Begg's and Mazumdar rank correlation with continuity correction and Egger's linear regression tests. Asymmetry of the collected studies' distribution by visual

inspection or P-value < 0.1 indicated obvious publication bias [19]. The Duval and Tweedie's trim and fill method's assumption were considered to reduce the bias in pooled estimates [20].

Results

204

205

206

207

208

209

210

211

212

213

214

215

216

217

218

219

220

221

222

Literature search

A flowchart outlining the systematic review search results is described in **Fig 1A**. A total of 4752 records were identified through four major electronic databases till April 22, 2020 including Web of Science (n = 557), PubMed (n = 1688), Scopus (n = 1688= 1105) and Science Direct (n = 1402). Upon reviewing the retrieved articles, a total of 1230 records were excluded for duplication, and 3522 unique records were initially identified. Following screening of titles and abstracts, several studies were excluded for being case records (n = 44), review articles (n = 262), irrelevant publications (n = 1355), or editorial materials (n = 1809). The resulted 424 full-text publications were further assessed for eligibility, during which 372 records were removed for lacking sufficient laboratory data. Ultimately, a total of 52 eligible articles were included for the quantitative synthesis of this meta-analysis study, with 52 records represented single-arm analysis, 16 records represented two-arms severity analysis; meanwhile, 7 and 4 records were utilized for survival and ICU admission analyses, respectively.

Fig 1. Literature search process.

- (A) Workflow for screening and selecting relevant articles. (B) Map showing the
- location of the studies. Studies conducted in China (red), Taiwan (green),
- Singapore (blue), and USA (light blue) are shown with the number of studies
- between brackets. Data source Tableau 2020.1 Desktop Professional Edition
- 228 (https://www.tableau.com/).

223

229

Characteristics of the included studies

Our review included 52 studies that were published from January 24 through April 230 22, 2020, including 48 articles from China [Wuhan (30), Chongqing (4), Zhejiang 231 (4), Shanghai (2), Ningbo (1), Hong Kong (1), Shenzhen (1), Anhui (1), Macau 232 (1), Hainan (1), Jiangsu (1), and Beijing (1)], two articles from Singapore 233 [Singapore and Sengkang], one article from Taiwan [Taichung], and one article 234 from USA [Washington] (Fig 1B). The main characteristics of eligible studies are 235 shown in **Table 1**. A total of 6320 patients with SARS \(\text{CoV} \(\text{ } \)2 infection were 236 enrolled across the articles. Most records (n = 47) were retrospective case studies, 237 while other study design included two prospective cohort studies, 238 observational cohort study, one descriptive case series, and one case-control study. 239 240 Our team stratified 36 different laboratory parameters into seven subclasses, including complete blood picture, coagulation profile, immunological markers, 241 immunoglobulins, complement tests, interleukins, and immune cells, as previously 242 described in the methodology. Regarding quality score assessment, 39 studies 243 achieved a score higher than six out of a maximum of nine (high quality), while the 244

- remaining 13 studies earned a score equal or lower than six (low quality), as shown
- 246 in **Table 1**.

Table 1. General characteristics of the included studies

First	Year	Publication	Journal name	Continent	Country	Study design	Sample	Quality	Seference no [35] [36] [37] [38] [27] [39] [40] [41] [42] [43] [9] [44] [45] [46] [47] [48] [49] [50] [51] [52] [53] [54] [55] [56] [57] [58] [59] [60] [61] [62] [63] [64] [65] [65]
Author		date (dd-mm)					size	score	
Zhu Z	2020	22-April	International J of Infectious Diseases	Ningbo	China	Retrospective case study	127	9	[35]
Liu X	2020	20-April	Acta Pharm Sin B	Wuhan	China	Retrospective case study	124	8	[36]
Chen X	2020	18-April	Clin Infect Dis	Wuhan	China	Retrospective case study	48	9	[37]
Chen G	2020	13-April	J Clinical Invest	Wuhan	China	Retrospective case study	21	8	[38]
He R	2020	12-April	J Clinical Virology	Wuhan	China	Retrospective case study	204	9	[27]
Zhang G	2020	09-April	J Clinical Virology	Wuhan	China	Retrospective case study	221	9	[39]
Lei S	2020	04-April	EClinicalMedicine	Wuhan	China	Retrospective case study	34	9	[40]
Wang L	2020	30-March	Journal of Infection	Wuhan	China	Retrospective case study	339	8	[41]
Guo T	2020	27-March	JAMA Cardiology	Wuhan	China	Retrospective case study	187	8	[42]
Zheng C	2020	27-March	Int J Infect Dis	Wuhan	China	Retrospective case study	55	7	[43]
Chen T	2020	26-March	BMJ	Wuhan	China	Retrospective case study	274	9	[9]
Tang X	2020	26-March	Chest	Wuhan	China	Retrospective case study	73	6	[44]
Shi S	2020	25-March	JAMA Cardiology	Wuhan	China	Retrospective case study	416	9	[45]
то к	2020	23-March	Lancet Infectious Diseases	Hong Kong	China	Observational cohort study	23	9	[46]
Zhou Z	2020	24-March	Eur Radiol	Chongqing	China	Retrospective case study	62	9	[47]
Chen Z	2020	24-March	European Journal of Radiology	Zhejiang	China	Retrospective case study	98	6	[48]
Wan S	2020	21-March	J Med Virol	Chongqing	China	Retrospective case study	135	9	[49]
Cheng Y	2020	20-March	Kidney International	Wuhan	China	Prospective cohort study	701	9	[50]
Luo S	2020	20-March	Clin Gastroenterol Hepatol	Wuhan	China	Retrospective case study	183	5	[51]
Deng Y	2020	20-March	Chin Med J (Engl)	Wuhan	China	Retrospective case study	225	8	[52]
Arentz M	2020	19-March	JAMA	Washington	USA	Retrospective case study	21	5	[53]
Chen J	2020	19-March	Journal of Infection	Shanghai	China	Retrospective case study	249	5	[54]
Cai Q	2020	18-March	Engineering	Shenzhen	China	Retrospective case study	80	9	[55]
Gao Y	2020	17-March	J Med Virol	Anhui	China	Retrospective case study	43	9	[56]
Qian G	2020	17-March	QJM	Zhejiang	China	Retrospective case study	91	5	[57]
Mo P	2020	16-March	Clin Infect Dis	Wuhan	China	Retrospective case study	155	8	[58]
Wang Z	2020	16-March	Clin Infect Dis	Wuhan	China	Retrospective case study	69	7	[59]
Lo I	2020	15-March	Int J Biol Sci	Macau	China	Retrospective case study	10	8	[60]
Cheng Z	2020	14-March	AJR Am J Roentgenol	Shanghai	China	Retrospective case study	11	5	[61]
Hsih W	2020	13-March	J Microbiol Immunol Infect	Taichung	Taiwan	Retrospective case study	2	5	[62]
Wu C	2020	13-March	JAMA Internal Medicine	Wuhan	China	Retrospective case study	201	8	[63]
Qin C	2020	12-March	Clin Infect Dis	Wuhan	China	Retrospective case study	452	9	[64]
Zhao D	2020	12-March	Clin Infect Dis	Wuhan	China	Case-control study	19	7	[65]

Liu K	2020	11-March	Journal of Infection	Hainan	China	Retrospective case study	18	7	[66]
Zhou F	2020	09-March	The Lancet	Wuhan	China	Retrospective case study	191	9	[67]
Xiong Y	2020	07-March	Invest Radiol	Wuhan	China	Retrospective case study	42	5	[68]
Fan B	2020	04-March	American journal of hematology	Singapore	Singapore	Retrospective case study	67	9	[69]
Young B	2020	03-March	JAMA	Sengkang	Singapore	Descriptive case series	18	7	[70]
Wu J	2020	29-February	Clin Infect Dis	Jiangsu	China	Retrospective case study	80	7	[71]
Li K	2020	29-February	Invest Radiol	Chongqing	China	Retrospective case study	83	9	[72]
Liu W	2020	28-February	Chin Med J (Engl)	Wuhan	China	Retrospective case study	78	9	[73]
Yang W	2020	26-February	Journal of Infection	Zhejiang	China	Retrospective case study	149	6	[74]
Wu J	2020	25-February	Invest Radiol	Chongqing	China	Retrospective case study	80	6	[75]
Shi H	2020	24-February	Lancet Infectious Diseases	Wuhan	China	Retrospective case study	81	7	[76] _{>}
Yang X	2020	24-February	The Lancet Respiratory Medicine	Wuhan	China	Retrospective case study	52	9	[77]
Zhang J	2020	23-February	Allergy	Wuhan	China	Retrospective case study	138	9	[78] hts
Zhou W	2020	21-February	Signal Transduction and Targeted Therapy	Wuhan	China	Retrospective case study	15	8	[79]
Xu X	2020	19-February	BMJ	Zhejiang	China	Retrospective case study	62	7	[77]
Pan F	2020	13-February	Radiology	Wuhan	China	Retrospective case study	21	6	[81]
Chang D	2020	07-February	JAMA	Beijing	China	Retrospective case study	13	6	[82]
Wang D	2020	07-February	JAMA	Wuhan	China	Retrospective case study	138	9	[83]
Huang C	2020	24-January	The Lancet	Wuhan	China	Prospective cohort study	41	9	[1]

Pooled estimates of laboratory parameters: Single-arm Meta-

analysis

248

249

250

251

252

253

254

255

256

257

258

259

260

261

The final pooled estimates of single-arm meta-analysis included 52 eligible articles. The pooled mean of laboratory parameters and 95%CI among SARS-CoV-2 infected patients, including hematological, immunological, and inflammatory variables, is illustrated in Table 2. Our results depicted a wide between studies for each laboratory marker. Apart from immunoglobulins, IL-2R, and IL-8, significant heterogeneity was observed. Subgroup analysis by sample size and city of origin and sensitivity analysis failed to reveal the source of variation for each parameter. Additionally, meta-regression also rendered insignificant results.

Table 2. Pooled estimates of single-arm meta-analysis for laboratory parameters in COVID-19 patients

Laboratory testing	Number	Sample	Estimate	95% CI	P-	Q	P-value	I ²	T 2
	studies	size			value				
СВС									
White blood cells	47	5967	5.82	5.24, 6.40	< 0.001	7136.1	< 0.001	99.35	3.83
Neutrophil count	31	3814	3.70	3.48, 3.92	< 0.001	525.8	< 0.001	93.9	0.31
Lymphocyte count	45	6017	0.99	0.91, 1.08	< 0.001	7645.2	< 0.001	99.3	0.07
Monocyte count	18	2586	0.42	0.39, 0.44	< 0.001	263.7	< 0.001	93.5	0.003
Eosinophils count	4	546	0.02	0.01, 0.024	< 0.001	10.6	0.014	71.6	0.0
Red blood cells	2	507	4.42	3.81, 4.67	< 0.001	50.8	< 0.001	98.03	0.095
Hemoglobin	26	3114	129.1	125.0, 133.3	< 0.001	1504.3	< 0.001	98.3	103.4
Platelet count	34	4347	178.4	171.9, 184.9	< 0.001	390.2	< 0.001	91.5	273.5
Coagulation profile									

Prothrombin time	22	3287	12.38	11.8, 12.9	< 0.001	3415.7	< 0.001	99.3	1.905
APTT	19	3023	31.8	30.2, 33.4	< 0.001	1312.1	< 0.001	98.6	11.96
Thrombin time	2	754	21.9	8.29, 35.57	0.002	1908.1	< 0.001	99.94	96.86
D-dimer	27	3857	1.25	0.67, 1.82	< 0.001	40947.5	< 0.001	99.9	2.22
Fibrinogen	2	781	2.45	0.61, 4.29	0.009	46.19	< 0.001	97.83	1.729
Inflammatory									
markers									
Ferritin	8	528	889.5	773.2, 1005.7	< 0.001	16.61	0.020	57.8	14138.9
ESR	13	1013	37.85	29.07, 46.6	< 0.001	692.4	< 0.001	98.26	239.7
Procalcitonin	25	3010	0.10	0.07, 0.12	< 0.001	3913.6	< 0.001	99.3	0.003
C-reactive protein	36	4409	28.11	24.7, 31.4	< 0.001	3432.1	< 0.001	98.9	79.35
Immunoglobulins									
IgA	2	101	2.21	2.15, 2.27	< 0.001	0.089	0.76	0.0	0.0
IgG	2	101	11.54	11.2, 11.8	< 0.001	1.88	0.17	46.9	0.023
IgM	2	101	1.00	0.96, 1.04	< 0.001	1.11	0.29	10.32	0.0
Complement test									
C3	2	101	0.95	0.80, 1.10	< 0.001	28.02	< 0.001	96.43	0.011
C4	2	101	0.24	0.21, 0.27	< 0.001	28.08	< 0.001	96.44	0.0
Interleukins									
IL-2R	2	101	762.3	732.4, 792.2	< 0.001	0.33	0.56	0.0	0.0
IL-4	2	276	2.98	1.09, 4.87	0.002	958.765	< 0.001	99.9	1.85
IL-6	12	926	11.56	9.82, 13.3	< 0.001	144.7	< 0.001	92.4	6.19
IL-8	2	101	18.4	17.08, 19.84	< 0.001	1.54	0.21	35.3	0.39
IL-10	3	292	6.33	4.39, 8.27	< 0.001	133.1	< 0.001	98.4	2.89
TNF-α	3	292	6.72	1.33, 12.12	0.015	2933.6	< 0.001	99.9	22.7
Immune cells									
CD4 ⁺ T cells	6	296	361.1	254.0, 468.2	< 0.001	88.7	< 0.001	94.3	15973.1
CD8 ⁺ T cells	5	285	219.6	157.1, 282.0	< 0.001	46.17	< 0.001	91.3	4437.2
T lymphocytes	2	167	704.3	254.5, 1154.0	0.002	27.6	< 0.001	96.3	101500
				i	1		1	1	1

Test of association: standardized mean difference, Random model. 95% CI: 95% confidence interval, Q statistic: a measure of weighted squared deviations that denotes the ratio of the observed variation to the within-study error, I²: the ratio of true heterogeneity to total observed variation, T²: Tau squared, and it is referred to the extent of variation among the effects observed in different studies. Laboratory markers (INR and B lymphocytes) were reported in only one study thus were not shown. CBC: Complete blood picture, APTT: Activated partial thromboplastin time, ESR: Erythrocyte sedimentation rate. Ig: immunoglobulin, IL-2R: Interleukin-2 receptor, TNF- α: tumor necrosis factor-alpha.

270

271

272

273

274

275

276

277

278

279

280

281

282

283

284

285

286

287

288

Pooled estimates of laboratory parameters according to disease severity: Pairwise Meta-analysis Two-arms meta-analyses were then conducted for three pairwise comparisons; (1) Severe versus mild COVID, (2) ICU admitted patients versus the general ward, and (3) Expired *versus* survivors (**Table 3**). Laboratory parameters of 16 eligible records were utilized to compare between severe and non-severe patients. Severe cohorts were more likely to have high blood levels of white blood cells (OR = 1.75, 95% CI = 1.21 - 2.54, p = 0.002), neutrophil count (OR = 2.62, 95%CI = 1.72 - 3.97, p < 0.001), prothrombin time (OR = 1.82, 95%CI = 1.00 - 3.33, p = 0.047), D-dimer (OR = 3.97, 95%CI = 2.62 - 6.02, p = 0.047) <0.001), fibrinogen (OR = 3.14, 95%CI = 1.64 - 6.00, p <0.001), erythrocyte sedimentation rate (OR = 1.60, 95% CI = 1.16 - 2.22, p < 0.001), procalcitonin (OR = 4.76, 95% CI = 2.48 - 9.14, p < 0.001), IL-6 (OR = 2.10, 95% CI = 1.02 - 4.32, p = 0.001)0.043), and IL-10 (OR = 4.93, 95%CI = 2.18 - 11.1, p < 0.001). In contrast, patients with normal lymphocyte count (OR = 0.30, 95%CI = 0.19 - 0.47, p < 0.001), platelet count (OR = 0.56, 95%CI = 0.42 - 0.74, p < 0.001), CD4⁺ T cells (OR = 0.04, 95% CI = 0.02 - 0.07, p < 0.001), and CD8⁺ T cells (OR = 0.03, 95% CI = 0.01 - 0.09, p < 0.001) were less likely to develop severe form of COVID-19 disease

(Table 3A).

289

295

Significant heterogeneity was observed in eight of these parameters, namely WBC

291 ($I^2 = 62.9\%$, p < 0.001), neutrophil count ($I^2 = 67.6\%$, p < 0.001), lymphocyte count

292 ($I^2 = 77.4\%$, p < 0.001), prothrombin time ($I^2 = 72\%$, p = 0.003), D-dimers ($I^2 = 72\%$)

293 55.6%, p = 0.021), procalcitonin ($I^2 = 86.1\%$, p < 0.001), IL-6 ($I^2 = 84.4\%$, p

294 <0.001), and IL-10 ($I^2 = 82.8\%$, p = 0.003).

Table 3. Pooled estimates of two-arms meta-analysis for laboratory parameters in COVID-19 patients.

Laboratory test	oratory test No of Sample size			I		Heterogeneity		
	studies			SMD (95%CI)	OR (95% CI)	P-	I ²	P-value
(A) Severity		Mild	Severe					
White blood cells	14	1007	634	0.31 (0.11, 0.52)	1.75 (1.21, 2.54)	0.002	62.9	< 0.001
Neutrophil count	14	959	599	0.53 (0.3, 0.76)	2.62 (1.72, 3.97)	< 0.001	67.61	< 0.001
Lymphocyte count	16	680	1128	-0.66 (-0.9, -0.41)	0.30 (0.19, 0.47)	< 0.001	77.36	< 0.001
Monocyte count	5	390	500	-0.08 (-0.23, 0.05)	0.86 (0.67, 1.12)	0.23	0.0	0.49
Hemoglobin	4	70	200	-0.22 (-0.51, 0.06)	0.67 (0.40, 1.12)	0.12	0.0	0.91
Platelet count	7	219	588	-0.32 (-0.47, -0.16)	0.56 (0.42, 0.74)	< 0.001	0.0	0.76
Prothrombin time	6	215	521	0.33 (0.004, 0.67)	1.82 (1.00, 3.33)	0.047	72.0	0.003
APTT	5	146	386	-0.23 (-0.79, 0.33)	0.66 (0.24, 1.82)	0.42	85.5	< 0.001
D-dimer	9	301	719	0.76 (0.53, 0.99)	3.97 (2.62, 6.02)	< 0.001	55.65	0.021
Ferritin	2	297	176	1.003 (-0.08, 2.09)	6.17 (0.87, 43.9)	0.07	79.21	0.028
Fibrinogen	3	45	144	0.63 (0.27, 0.99)	3.14 (1.64, 6.00)	< 0.001	0.0	0.81
ESR	2	302	277	0.26 (0.08, 0.44)	1.60 (1.16, 2.22)	0.004	0.0	0.43
Procalcitonin	10	565	716	0.86 (0.5, 1.22)	4.76 (2.48, 9.14)	< 0.001	86.1	< 0.001
C-reactive protein	13	605	928	1.02 (0.65, 1.4)	6.36 (3.22, 12.5)	< 0.001	88.2	< 0.001
IgA	2	355	301	0.13 (-0.03, 0.29)	1.27 (0.95, 1.69)	0.11	3.398	0.30
IgG	2	355	301	0.21 (-0.301, 0.72)	1.46 (0.58, 3.69)	0.41	88.3	0.003

IgM	2	355	301	-2.37 (-6.64, 1.89)	0.01 (0.00, 30.6)	0.27	99.56	< 0.001
Complement 3	2	355	301	0.18 (-0.1, 0.47)	1.39 (0.83, 2.32)	0.20	64.70	0.09
Complement 4	2	355	301	0.13 (-0.16, 0.43)	1.27 (0.74, 2.16)	0.38	66.83	0.08
IL-4	2	355	301	1.01 (-0.85, 2.87)	6.25 (0.2, 181.1)	0.28	97.17	< 0.001
IL-6	7	85	246	0.41 (0.014, 0.81)	2.10 (1.02, 4.32)	0.043	84.38	< 0.001
IL-10	3	371	412	0.88 (0.43, 1.33)	4.93 (2.18, 11.1)	< 0.001	82.81	0.003
TNF-α	3	371	412	0.6 (-0.17, 1.37)	2.97 (0.74, 11.9)	0.12	94.28	< 0.001
CD4 ⁺ T cells	2	80	145	-1.87 (-2.39, -1.36)	0.03 (0.01, 0.09)	< 0.001	29.8	0.23
CD8 ⁺ T cells	2	80	145	-1.8 (-2.12, -1.48)	0.04 (0.02, 0.07)	< 0.001	0.0	0.71
(B) Admission		Floor	ICU					
White blood cells	3	64	149	0.85 (0.54, 1.15)	4.67 (2.70, 8.10)	< 0.001	0.0	0.56
Neutrophil count	4	73	207	1.86 (0.59, 3.14)	29.1 (2.9, 291.8)	0.004	93.14	< 0.001
Lymphocyte count	4	73	207	-0.81 (-1.36, -0.27)	0.23 (0.09, 0.62)	0.003	68.59	0.023
Monocyte count	3	60	179	-0.308 (-1.15, 0.53)	0.57 (0.13, 2.59)	0.47	83.77	0.002
Hemoglobin	2	22	86	-1.1 (-1.97, -0.24)	0.14 (0.03, 0.64)	0.012	66.31	0.08
Platelet count	4	73	207	-0.06 (-0.33, 0.2)	0.90 (0.56, 1.45)	0.64	0.0	0.54
Prothrombin time	3	64	149	0.43 (0.09, 0.76)	2.18 (1.19, 3.99)	0.012	14.28	0.31
APTT	3	64	149	-0.22 (-0.51, 0.07)	0.67 (0.40, 1.13)	0.14	0.0	0.78
D-dimer	3	64	149	0.79 (0.35, 1.24)	4.19 (1.88, 9.35)	< 0.001	44.94	0.16
L dillioi	3	04	147	0.79 (0.33, 1.24)	4.19 (1.88, 9.35)	<0.001	44.24	0.10
(C) Mortality	3	Alive	Died	0.79 (0.33, 1.24)	4.19 (1.88, 9.35)	<0.001	44.94	0.10
	6			0.91 (0.61, 1.22)	5.21 (3.00, 9.05)	<0.001	78.05	<0.001
(C) Mortality		Alive	Died	, ,				
(C) Mortality White blood cells	6	Alive 736	Died 392	0.91 (0.61, 1.22)	5.21 (3.00, 9.05)	<0.001	78.05	<0.001
(C) Mortality White blood cells Neutrophil count	6 3	Alive 736 475	Died 392 222	0.91 (0.61, 1.22) 1.01 (0.4, 1.63)	5.21 (3.00, 9.05) 6.25 (2.05, 19.0)	<0.001	78.05 90.9	<0.001 <0.001
(C) Mortality White blood cells Neutrophil count Lymphocyte count	6 3 7	736 475 756	Died 392 222 424	0.91 (0.61, 1.22) 1.01 (0.4, 1.63) -0.85 (-1.28, -0.41)	5.21 (3.00, 9.05) 6.25 (2.05, 19.0) 0.21 (0.10, 0.47)	<0.001 0.001 <0.001	78.05 90.9 89.33	<0.001 <0.001 <0.001
(C) Mortality White blood cells Neutrophil count Lymphocyte count Monocyte count	6 3 7 4	736 475 756 483	Died 392 222 424 229	0.91 (0.61, 1.22) 1.01 (0.4, 1.63) -0.85 (-1.28, -0.41) -0.18 (-0.47, 0.1)	5.21 (3.00, 9.05) 6.25 (2.05, 19.0) 0.21 (0.10, 0.47) 0.72 (0.43, 1.21)	<0.001 0.001 <0.001 0.21	78.05 90.9 89.33 57.48	<0.001 <0.001 <0.001 0.070
(C) Mortality White blood cells Neutrophil count Lymphocyte count Monocyte count Hemoglobin	6 3 7 4 5	736 475 756 483 600	Died 392 222 424 229 271	0.91 (0.61, 1.22) 1.01 (0.4, 1.63) -0.85 (-1.28, -0.41) -0.18 (-0.47, 0.1) 0 (-0.15, 0.15)	5.21 (3.00, 9.05) 6.25 (2.05, 19.0) 0.21 (0.10, 0.47) 0.72 (0.43, 1.21) 1.00 (0.76, 1.31)	<0.001 0.001 <0.001 0.21 0.99	78.05 90.9 89.33 57.48 4.988	<0.001 <0.001 <0.001 0.070 0.378
(C) Mortality White blood cells Neutrophil count Lymphocyte count Monocyte count Hemoglobin Platelet count	6 3 7 4 5	736 475 756 483 600 640	Died 392 222 424 229 271 315	0.91 (0.61, 1.22) 1.01 (0.4, 1.63) -0.85 (-1.28, -0.41) -0.18 (-0.47, 0.1) 0 (-0.15, 0.15) -0.46 (-0.71, -0.21)	5.21 (3.00, 9.05) 6.25 (2.05, 19.0) 0.21 (0.10, 0.47) 0.72 (0.43, 1.21) 1.00 (0.76, 1.31) 0.43 (0.28, 0.68)	<0.001 0.001 <0.001 0.21 0.99 <0.001	78.05 90.9 89.33 57.48 4.988 59.52	<0.001 <0.001 <0.001 0.070 0.378 0.030
(C) Mortality White blood cells Neutrophil count Lymphocyte count Monocyte count Hemoglobin Platelet count Prothrombin time	6 3 7 4 5 6	736 475 756 483 600 640	Died 392 222 424 229 271 315 315	0.91 (0.61, 1.22) 1.01 (0.4, 1.63) -0.85 (-1.28, -0.41) -0.18 (-0.47, 0.1) 0 (-0.15, 0.15) -0.46 (-0.71, -0.21) 0.64 (0.25, 1.03)	5.21 (3.00, 9.05) 6.25 (2.05, 19.0) 0.21 (0.10, 0.47) 0.72 (0.43, 1.21) 1.00 (0.76, 1.31) 0.43 (0.28, 0.68) 3.19 (1.58, 6.47)	<0.001 0.001 <0.001 0.21 0.99 <0.001 0.001	78.05 90.9 89.33 57.48 4.988 59.52 83.0	<0.001 <0.001 <0.001 0.070 0.378 0.030 <0.001
(C) Mortality White blood cells Neutrophil count Lymphocyte count Monocyte count Hemoglobin Platelet count Prothrombin time APTT	6 3 7 4 5 6 6	736 475 756 483 600 640 640 483	Died 392 222 424 229 271 315 315 229	0.91 (0.61, 1.22) 1.01 (0.4, 1.63) -0.85 (-1.28, -0.41) -0.18 (-0.47, 0.1) 0 (-0.15, 0.15) -0.46 (-0.71, -0.21) 0.64 (0.25, 1.03) -0.096 (-0.51, 0.31)	5.21 (3.00, 9.05) 6.25 (2.05, 19.0) 0.21 (0.10, 0.47) 0.72 (0.43, 1.21) 1.00 (0.76, 1.31) 0.43 (0.28, 0.68) 3.19 (1.58, 6.47) 0.83 (0.40, 1.75)	<0.001 0.001 <0.001 0.21 0.99 <0.001 0.001 0.646	78.05 90.9 89.33 57.48 4.988 59.52 83.0 78.23	<0.001 <0.001 <0.001 0.070 0.378 0.030 <0.001 0.003
(C) Mortality White blood cells Neutrophil count Lymphocyte count Monocyte count Hemoglobin Platelet count Prothrombin time APTT D-dimer	6 3 7 4 5 6 6 4 5	736 475 756 483 600 640 640 483 620	Died 392 222 424 229 271 315 315 229 283	0.91 (0.61, 1.22) 1.01 (0.4, 1.63) -0.85 (-1.28, -0.41) -0.18 (-0.47, 0.1) 0 (-0.15, 0.15) -0.46 (-0.71, -0.21) 0.64 (0.25, 1.03) -0.096 (-0.51, 0.31) 1.02 (0.85, 1.18)	5.21 (3.00, 9.05) 6.25 (2.05, 19.0) 0.21 (0.10, 0.47) 0.72 (0.43, 1.21) 1.00 (0.76, 1.31) 0.43 (0.28, 0.68) 3.19 (1.58, 6.47) 0.83 (0.40, 1.75) 6.36 (4.72, 8.58)	<0.001 0.001 <0.001 0.21 0.99 <0.001 0.646 <0.001	78.05 90.9 89.33 57.48 4.988 59.52 83.0 78.23 10.63	<0.001 <0.001 <0.001 0.070 0.378 0.030 <0.001 0.003
(C) Mortality White blood cells Neutrophil count Lymphocyte count Monocyte count Hemoglobin Platelet count Prothrombin time APTT D-dimer Ferritin	6 3 7 4 5 6 6 4 5 3	736 475 756 483 600 640 483 620 338	Died 392 222 424 229 271 315 315 229 283 211	0.91 (0.61, 1.22) 1.01 (0.4, 1.63) -0.85 (-1.28, -0.41) -0.18 (-0.47, 0.1) 0 (-0.15, 0.15) -0.46 (-0.71, -0.21) 0.64 (0.25, 1.03) -0.096 (-0.51, 0.31) 1.02 (0.85, 1.18) 0.94 (0.26, 1.62)	5.21 (3.00, 9.05) 6.25 (2.05, 19.0) 0.21 (0.10, 0.47) 0.72 (0.43, 1.21) 1.00 (0.76, 1.31) 0.43 (0.28, 0.68) 3.19 (1.58, 6.47) 0.83 (0.40, 1.75) 6.36 (4.72, 8.58) 5.50 (1.6, 18.83)	<0.001 0.001 <0.001 0.21 0.99 <0.001 0.001 0.646 <0.001 0.006	78.05 90.9 89.33 57.48 4.988 59.52 83.0 78.23 10.63 91.63	<0.001 <0.001 <0.001 0.070 0.378 0.030 <0.001 0.003 0.34 <0.001
(C) Mortality White blood cells Neutrophil count Lymphocyte count Monocyte count Hemoglobin Platelet count Prothrombin time APTT D-dimer Ferritin ESR	6 3 7 4 5 6 6 4 5 3 2	Alive 736 475 756 483 600 640 483 620 338 201	Died 392 222 424 229 271 315 315 229 283 211 157	0.91 (0.61, 1.22) 1.01 (0.4, 1.63) -0.85 (-1.28, -0.41) -0.18 (-0.47, 0.1) 0 (-0.15, 0.15) -0.46 (-0.71, -0.21) 0.64 (0.25, 1.03) -0.096 (-0.51, 0.31) 1.02 (0.85, 1.18) 0.94 (0.26, 1.62) 0.33 (0.08, 0.58)	5.21 (3.00, 9.05) 6.25 (2.05, 19.0) 0.21 (0.10, 0.47) 0.72 (0.43, 1.21) 1.00 (0.76, 1.31) 0.43 (0.28, 0.68) 3.19 (1.58, 6.47) 0.83 (0.40, 1.75) 6.36 (4.72, 8.58) 5.50 (1.6, 18.83) 1.82 (1.16, 2.86)	<0.001 0.001 <0.001 0.21 0.99 <0.001 0.646 <0.001 0.006 0.008	78.05 90.9 89.33 57.48 4.988 59.52 83.0 78.23 10.63 91.63 20.03	<0.001 <0.001 <0.001 0.070 0.378 0.030 <0.001 0.003 0.34 <0.001 0.263
(C) Mortality White blood cells Neutrophil count Lymphocyte count Monocyte count Hemoglobin Platelet count Prothrombin time APTT D-dimer Ferritin ESR Procalcitonin	6 3 7 4 5 6 6 4 5 3 2	Alive 736 475 756 483 600 640 483 620 338 201 580	Died 392 222 424 229 271 315 315 229 283 211 157 239	0.91 (0.61, 1.22) 1.01 (0.4, 1.63) -0.85 (-1.28, -0.41) -0.18 (-0.47, 0.1) 0 (-0.15, 0.15) -0.46 (-0.71, -0.21) 0.64 (0.25, 1.03) -0.096 (-0.51, 0.31) 1.02 (0.85, 1.18) 0.94 (0.26, 1.62) 0.33 (0.08, 0.58) 0.96 (0.43, 1.49)	5.21 (3.00, 9.05) 6.25 (2.05, 19.0) 0.21 (0.10, 0.47) 0.72 (0.43, 1.21) 1.00 (0.76, 1.31) 0.43 (0.28, 0.68) 3.19 (1.58, 6.47) 0.83 (0.40, 1.75) 6.36 (4.72, 8.58) 5.50 (1.6, 18.83) 1.82 (1.16, 2.86) 5.70 (2.18, 14.9)	<0.001 0.001 <0.001 0.21 0.99 <0.001 0.646 <0.001 0.006 0.008	78.05 90.9 89.33 57.48 4.988 59.52 83.0 78.23 10.63 91.63 20.03 81.48	<0.001 <0.001 <0.001 0.070 0.378 0.030 <0.001 0.003 0.34 <0.001 0.263 0.005
(C) Mortality White blood cells Neutrophil count Lymphocyte count Monocyte count Hemoglobin Platelet count Prothrombin time APTT D-dimer Ferritin ESR Procalcitonin C-reactive protein	6 3 7 4 5 6 6 4 5 3 2 3 4	Alive 736 475 756 483 600 640 640 483 620 338 201 580 591	Died 392 222 424 229 271 315 315 229 283 211 157 239 331	0.91 (0.61, 1.22) 1.01 (0.4, 1.63) -0.85 (-1.28, -0.41) -0.18 (-0.47, 0.1) 0 (-0.15, 0.15) -0.46 (-0.71, -0.21) 0.64 (0.25, 1.03) -0.096 (-0.51, 0.31) 1.02 (0.85, 1.18) 0.94 (0.26, 1.62) 0.33 (0.08, 0.58) 0.96 (0.43, 1.49) 1.08 (0.65, 1.52)	5.21 (3.00, 9.05) 6.25 (2.05, 19.0) 0.21 (0.10, 0.47) 0.72 (0.43, 1.21) 1.00 (0.76, 1.31) 0.43 (0.28, 0.68) 3.19 (1.58, 6.47) 0.83 (0.40, 1.75) 6.36 (4.72, 8.58) 5.50 (1.6, 18.83) 1.82 (1.16, 2.86) 5.70 (2.18, 14.9) 7.09 (3.23, 15.5)	<0.001 0.001 0.001 0.21 0.99 <0.001 0.646 <0.001 0.006 0.008 <0.001 <0.001	78.05 90.9 89.33 57.48 4.988 59.52 83.0 78.23 10.63 91.63 20.03 81.48 87.31	<0.001 <0.001 <0.001 <0.001 0.070 0.378 0.030 <0.001 0.003 0.34 <0.001 0.263 0.005 <0.001

Continuous Random-Effects model, SMD: Standardized mean difference, OR 95% CI: Odds ratio 95% 298 confidence interval, I²: the ratio of true heterogeneity to total observed variation. APTT: Activated 299 partial thromboplastin time, ESR: Erythrocyte sedimentation rate. Ig: immunoglobulin, IL: Interleukin, 300 301 TNF-α: tumor necrosis factor-alpha. Pooled estimates of laboratory parameters according to ICU 302 admission: Pairwise Meta-analysis 303 A total of 4 eligible articles were recognized to include laboratory features of ICU 304 and floor patients. Our data revealed having elevated levels of WBCs (OR = 5.21, 305 95%CI = 3.0 - 9.05, p < 0.001), neutrophils (OR = 6.25, 95%CI = 2.05 - 19.0, p =306 0.001), D-dimer (OR = 4.19, 95%CI = 1.88 - 9.35, p < 0.001), and prolonged 307 prothrombin time (OR = 2.18, 95%CI = 1.19 - 3.99, p = 0.012) were associated 308 with increased odds of ICU admission, while normal lymphocyte count (OR = 309 0.23, 95% CI = 0.09 - 0.62, p = 0.003) and hemoglobin (OR = 0.14, 95% CI = 0.03 - 0.03310 0.64, p = 0.012) conferred lower risk of ICU admission (**Table 3B**). 311 Remarkable heterogeneity was obvious in studies of neutrophil count ($I^2 = 93.1\%$, 312 p < 0.001), lymphocyte count ($I^2 = 68.5\%$, p = 0.023), and hemoglobin ($I^2 = 66.3\%$). 313 p = 0.08). These parameters were enclosed in two to four studies; therefore, further 314

Pooled estimates of laboratory parameters according to mortality:

tracing for the source of heterogeneity was not applicable.

315

Pairwise Meta-analysis

317

Of the included articles, 7 studies contained separate results for laboratory testing 318 in survival versus expired patients. As depicted in Table 3C, our data revealed 319 increased odds of having elevated levels of WBC (OR = 5.21, 95%CI = 3.0 - 9.05,320 p < 0.001), neutrophils (OR = 6.25, 95%CI = 2.05 – 19.0, p = 0.001), prothrombin 321 time (OR = 3.19, 95%CI = 1.58 - 6.47, p = 0.001), D-dimer (OR = 6.36, 95%CI = 322 4.72 - 8.58, p < 0.001), ferritin (OR = 5.50, 95%CI = 1.6 - 18.8, p = 0.006), ESR 323 (OR = 1.82, 95% CI = 1.16 - 2.86, p = 0.008), procalcitonin (OR = 5.70, 95% CI = 1.16 - 2.86, p = 0.008)324 2.18 - 14.9, p < 0.001), CRP (OR = 7.09, 95%CI = 3.23 - 15.5, p < 0.001), and IL-6 325 (OR = 13.87, 95%CI = 7.6 - 25.4, p < 0.001) in expired cases. However, patients 326 with normal lymphocyte count (0.21 (0.10, 0.47, p < 0.001), platelet count (0.43 327 $(0.28, 0.68, p < 0.001), CD4^{+} T cells (OR = 0.30 (0.16, 0.55, p < 0.001), and CD8^{+}$ 328 T cells (OR = 0.22 (0.15, 0.34, p < 0.001) had higher chance of survival (**Table** 329 **3C**). 330 Considerable heterogeneity was also noted in some of these parameters, namely 331 WBC ($I^2 = 78.0\%$, p <0.001), neutrophilic count ($I^2 = 90.9\%$, p <0.001), 332 lymphocyte count ($I^2 = 89.3\%$, p < 0.001), platelet count ($I^2 = 59.5\%$, p = 0.030), 333 ferritin ($I^2 = 91.6\%$, p < 0.001), procalcitonin ($I^2 = 81.5\%$, p = 0.005), CRP ($I^2 = 91.6\%$) 334 87.3%, p < 0.001), and IL-6 ($I^2 = 75.4\%$, p = 0.007). Given the small number of 335 enrolled studies with discriminated data on patients who survived or died, we 336

failed to identify the source of heterogeneity.

Subgroup and sensitivity analysis

337

338

339

340

341

342

343

344

345

346

347

348

349

350

351

352

353

354

355

For the studies which included a comparison between mild and severe patients, subgroup and sensitivity analyses were performed for five laboratory markers (WBC, neutrophil count, lymphocyte count, procalcitonin, and CRP). First, to identify how each study affects the overall estimate of the rest of the studies, we performed leave-one-out sensitivity analyses. Results did not contribute to give explanations to heterogeneity. In contrast, subgroup analysis revealed homogeneity with certain categorizations. For WBCs lab results, heterogeneity was resolved on stratification by the origin of study population [Wuhan population: $I^2 = 73.4\%$, p =0.002, other cities: $I^2 = 0\%$, p = 0.53] and month of publication [April: $I^2 = 74.5\%$, p = 0.001, February/March: $I^2 = 47.5\%$, p = 0.06]. Regarding neutrophilic count, the variance in the results resolved in articles with large sample size >50 patients $(I^2 = 46.2\%, p = 0.06)$. Moreover, the degree of dissimilarities of procalcitonin results found in different studies was ameliorated in April publications ($I^2 = 41.5\%$, p = 0.16) and in those with low sample size ($I^2 = 0\%$, p = 0.80). Similarly, homogeneity was generated in CRP results in articles with low sample size (I^2 = 0%, p = 0.58) (**Table 4**).

Meta-regression analysis

Considering the number of the included studies with severity, ICU admission, and mortality data was rather small, we performed meta-regression analyses for only five parameters (mentioned above) in studies comparing mild and severe disease (**Table 4**).

Table 4. Tracing the source of heterogeneity of laboratory markers in studies comparing mild and severe COVID-19 patients

360

Lab test	Feature	Categories	Count of	Pooled	estimate	S		Heteroge	neity	Meta-regression			
			studies	SMD	LL	UL	P-value	\mathbf{I}^2	P-value	Coefficient	LL	UL	P-value
White blood	Overall		14	0.317	0.113	0.52	0.002	62.90%	0.001				
cells	Origin of	Others	8	0.113	-0.083	0.308	0.26	0%	0.53	Reference			
	patients	Wuhan	6	0.490	0.198	0.783	0.00	73.40%	0.002	0.31	0.03	0.58	0.029
	Sample	≤50	5	0.164	-0.553	0.881	0.65	71.30%	0.007	Reference			
	size	>50	9	0.387	0.208	0.566	< 0.001	52.60%	0.031	0.30	-0.10	0.72	0.14
	Publication	Feb/Mar	8	0.251	0.039	0.464	0.021	47.50%	0.06	Reference			
	month	April	6	0.445	0.005	0.884	0.047	74.50%	0.001	0.11	-0.16	0.38	0.43
Neutrophils	Overall		14	0.534	0.306	0.762	< 0.001	67.62%	< 0.001				
	Origin of	Others	8	0.439	0.139	0.740	0.004	50.88%	0.047	Reference			
	patients	Wuhan	6	0.632	0.280	0.985	< 0.001	78.29%	< 0.001	0.045	-0.21	0.30	0.20
	Sample	≤50	5	0.286	-0.503	1.076	0.47	75.94%	0.002	Reference			
	size	>50	9	0.65	0.472	0.828	< 0.001	46.2%	0.06	0.606	0.20	1.01	0.003
	Publication	Feb/Mar	8	0.428	0.181	0.675	< 0.001	54.4%	0.032	Reference			
	month	April	6	0.709	0.273	1.44	0.001	73.19%	0.002	0.312	0.06	0.55	0.014
Lymphocytes	Overall		16	-0.663	-0.909	-0.417	< 0.001	77.36%	< 0.001				
	Origin of	Others	9	-0.626	-0.962	-0.291	< 0.001	66.51%	0.002	Reference			
	patients	Wuhan	7	-0.710	1.097	-0.323	< 0.001	85.72%	< 0.001	0.092	-0.31	0.49	0.64
	Sample	≤50	5	-0.506	-1.169	0.156	0.13	66.1%	0.019	Reference			
	size	>50	11	-0.714	-0.983	-0.444	< 0.001	80.98%	< 0.001	-0.342	-0.85	0.169	0.18
	Publication	Feb/Mar	9	-0.452	-0.712	-0.192	< 0.001	66.65%	0.002	Reference			
	month	April	7	-0.979	-1.354	-0.604	< 0.001	70.53%	0.002	-0.572	-0.97	-0.17	0.006
Procalcitonin	Overall		10	0.868	0.508	1.228	< 0.001	88.16%	< 0.001				

	Origin of	Others	5	1.038	0.370	1.706	< 0.001	86.16%	< 0.001	Reference			
	patients	Wuhan	5	0.686	0.331	1.041	< 0.001	75.38%	0.003	-0.318	-0.97	0.33	0.34
	Sample	≤50	3	0.768	0.334	1.203	< 0.001	0%	0.80	Reference			
	size	>50	7	0.903	0.459	1.348	< 0.001	88.62%	< 0.001	0.054	-0.72	0.83	0.89
	Publication	Feb/Mar	6	0.956	0.404	1.509	< 0.001	91.51%	< 0.001	Reference			
	month	April	4	0.757	0.409	1.105	< 0.001	41.54%	0.16	-0.096	-0.80	0.61	0.78
C-reactive	Overall		13	1.027	0.65	1.40	< 0.001	88.2%	< 0.001				
protein	Origin of	Others	8	1.24	0.65	1.83	< 0.001	87.8%	< 0.001	Reference			
	patients	Wuhan	5	0.389	0.30	1.07	< 0.001	80.7%	< 0.001	-0.58	-1.27	0.10	0.09
	Sample	≤50	3	0.831	0.341	1.322	< 0.001	0%	0.58	Reference			
	size	>50	10	1.08	0.651	1.512	< 0.001	82.3%	< 0.001	0.37	-0.55	1.29	0.42
	Publication	Feb/Mar	8	1.014	0.502	1.525	< 0.001	88.23%	< 0.001	Reference			
	month	April	5	1.07	0.548	1.600	< 0.001	75.1%	0.003	0.13	-0.59	0.86	0.71
		1		- 1	1	1			1	-	-1	1	

362 SMD: Standardized mean difference, LL: lower limit, UL: upper limit, I²: the ratio of true heterogeneity to total observed variation.

363 Significant values indicate significance at P < 0.05.

For WBCs, higher difference between mild and severe cohorts was noted in Wuhan studies than other population (coefficient = 0.31, 95%CI = 0.03, 0.58, p = 0.029). Moreover, articles with larger sample size exhibited a wider variation of neutrophilic count between severe and non-severe cases (coefficient = 0.60, 95%CI = 0.20, 1.01, p = 0.003). For the same marker, later studies published in April also showed higher difference compared to those published in February and March (coefficient = 0.31, 95%CI = 0.06, 0.55, p = 0.014). In contrast, more reduction of lymphocytes was observed in April articles than earlier ones (coefficient = -0.57, 95%CI = -0.97, -0.17, p = 0.006).

Publication bias

Publication bias was performed to the same five parameters with study count ≥ 10 (**Fig. S1**). Visual inspection of the funnel plots suggested symmetrical distribution for all laboratory parameters tested. The Egger test (p > 0.1) confirmed that there was no substantial evidence of publication bias; Egger's regression p values were 0.44, 0.50, 0.68, 0.56, and 0.22 for WBC, neutrophil count, lymphocyte count, procalcitonin, and CRP, respectively.

Decision tree and Receiver Operating Characteristic (ROC) curve

To identify predictors for severity, decision tree analysis was applied using multiple laboratory results. High performance of classification was found with the

usage of a single parameter; neutrophilic count identified severe patients with 100% sensitivity and 81% specificity at a cut-off value of >3.74 identified by the specified decision tree model. Further analysis of the area under the curve of input data is shown in **Table 5**.

Table 5. Receiver Operating Characteristics results

Lab test	AUC	Threshold	Sensitivity	Specificity	P-value
WBC	0.801 ± 0.09	5.47	85.7	85.7	0.007
Neutrophil	0.831 ± 0.09	3.74	78.5	100	0.003
Lymphocyte	0.867 ± 0.06	0.98	81.2	87.5	<0.001
Platelets	0.836 ± 0.11	177.6	71.4	71.4	0.035
PT	0.583 ± 0.17	12.9	50.0	83.3	0.63
Procalcitonin	0.845 ± 0.09	0.06	80.0	90.0	0.007
D-dimer	0.876 ± 0.08	0.48	88.9	77.8	0.007
CRP	0.875 ± 0.08	38.2	84.6	92.3	0.001
IL-6	0.632 ± 1.6	22.9	71.4	71.4	0.40

AUC: area under the curve, WBC: white blood cells, PT: prothrombin time, CRP: C-reactive protein, IL-6: interleukin 6. Bold values indicate significance at P < 0.05.

Trial sequential analysis

As elaborated by the decision tree algorithm for the role of neutrophilic count on decision-making to discriminate between COVID-19 patients with a mild and severe presentation, TSA was employed on that particular laboratory parameter to

test for the presence of sufficient studies from which results were drawn. The sample size of studies containing neutrophilic count information and classifying cohorts into mild and severe COVID-19 infection accounted for a total of 1,558 subjects. TSA illustrated crossing of the monitoring boundary by the cumulative Z-curve before reaching the required sample size, suggesting that the cumulative proof was acceptable, and no additional future studies are needed to authenticate the significances (**Fig 2**).

Fig 2 Trial sequential analysis. Trial sequential analysis (TSA) for the neutrophil count. The obtained sample size of the neutrophil count was 1558 subjects and the cumulative Z-curve crossed the monitoring boundary before reaching the required sample size, suggesting that the cumulative proof was reliable, and no additional trials are required to achieve the significances.

Discussion

During the last few months, the prevalence of COVID-19 infection was increased daily among different countries overall in the world. Thus, the need to assess the disease severity and mortality are required to limit the pervasiveness of this pandemic [21]. A diverse of abnormal laboratory parameters including hematological, inflammatory as well as immunological markers thought to be

415

416

417

418

419

420

421

422

423

424

425

426

427

428

429

430

431

432

433

raised throughout COVID-19 outbreak [2, 22]. In this comprehensive metaanalysis, our team attempted to interpret the distinct questions raised about the various spectrum of laboratory parameters associated with the severity and mortality of COVID-19. At the beginning of this workflow, our team investigated different hematological, inflammatory, and immunological variables of 6320 patients diagnosed with COVID-19. Our findings using random-effect models revealed increased levels of WBCs and neutrophil counts that were significantly associated with higher odds ratio among severe, ICU admission and Expired patients with COVID-19. On the contrary, the levels of lymphocyte and platelet counts were lowered among severe and expired patients with COVID-19. Also, we observed depletion in quantities of CD4⁺ T cells and CD8⁺ T cells among severe and mortality patients. Nevertheless, in patients with the COVID-19 outbreak, the WBC count can vary [23]. Other reports indicated that leukopenia, leukocytosis, and lymphopenia have been reported, although lymphopenia appears most common [24, 25]. Another study supported that lymphopenia is an effective and reliable indicator of the severity and hospitalization in COVID-19 patients [26]. The additional report suggested that COVID-19 illness might be implicated with CD4⁺ and CD8⁺ T cells depletion through acting on lymphocytes, especially T lymphocytes [27]. A recent meta-analysis study discovered that the severity among COVID-19 patients might

435

436

437

438

439

440

441

442

443

444

445

446

447

448

449

450

451

452

453

correlate with higher levels of WBCs count and lower levels of lymphocyte, CD4⁺ T cells, and CD8⁺ T cells counts [22]. In this respect, we could speculate that the depletion in the number of lymphocytes count is directly proportional with the severity of COVID-19 infection and the high survival rate of the disease is associated with the ability to renovate lymphocyte cells, particularly T lymphocytes which are crucial for destroying the infected viral particles [28]. During disease severity, remarkable thrombocytopenia was observed and confirmed by Lippi and his colleagues that revealed a reduction of platelet count among severe and died patients with COVID-19 supporting that thrombocytopenia could consider as an exacerbating indicator during the progression of the disease [29]. Therefore, our findings could support Shi et al. conclusion that high WBC count with lymphopenia could be considered as a differential diagnostic criterion for COVID-19 [30]. Considering coagulation profile, our team observed a prolonged in most coagulation markers among severe, ICU and expired patients, especially prothrombin time, fibringen, D-dimer, but with normal proportions of activated partial thromboplastin time (APTT) that could focus the light on the pathogenesis of COVID-19 infection through interfering with extrinsic coagulation pathway. A recently published report concluded similar findings in the form of observation of higher levels prothrombin time, D-dimer along fibrin degradation products among

455

456

457

458

459

460

461

462

463

464

465

466

467

468

469

470

471

472

473

non-survival compared with survival patients [31]. Numerous studies illustrated the pathogenesis action of COVID-19 with the induction of cytokine storm throughout the progressive phase of the infection [22, 32, 33]. The generation of cytokine storm within COVID-19 patients required increased levels of IFN-γ and IL-1β that could stimulate the cellular response of T helper type 1 (Th1) which has a crucial function in the acceleration of specific immunity against COVID-19 outbreak [32]. Due to the elevated levels of IL-2R and IL-6 accompanied by the advancement of COVID-19, several cytokines secreted by T helper type 2 (Th2) cells that could neutralize the inflammatory responses including IL-4 and IL-10 [22, 32]. Our findings revealed a significantly associated with elevated levels of anti-inflammatory cytokines involving IL-6 and IL-10 among severe and expired patients with COVID-19. A recent study indicated a similar assumption with these findings and identified elevated levels of IL-6 and IL-10 among non-survived compared with survived patients [9]. Another confirmation of this conclusion is confirmed by a newly published meta-analysis report that indicated an exaggerated elevation of IL-6 and IL-10 throughout the severe level of COVID-19 infection [22]. Concerning the inflammatory markers associated with the COVID-19 pandemic, this comprehensive meta-analysis study observed higher concentrations of Creactive protein (CRP) procalcitonin besides elevated erythrocyte and

475

476

477

478

479

480

481

482

483

484

485

486

487

488

489

490

491

492

493

sedimentation rate (ESR) levels among severe and expired patients with COVID-19. Recently, Henry et al. established a meta-analysis survey and corroborated this finding with a higher significance of CRP and procalcitonin levels [22]. Other recent reports identified higher levels of CRP among severe patients with COVID-19 infection [26]. An additional meta-analysis survey established based on four recent articles indicated prolonged levels of procalcitonin among severe patients with COVID-19 [34]. In this respect, we might speculate the potential role of procalcitonin as a prognostic biomarker during the severe status of COVID-19. Finally, our team revealed increased levels of serum ferritin among non-survived patients compared with survived patients, and this significant outcome was observed in another meta-analysis study among severe and non-survival patients with COVID-19 infection [22]. This comprehensive meta-analysis confronted several limitations that raised throughout the processing of the outcomes. First, the insufficient laboratory data concerning the interest of design causing the increasing bias among different covariates. Second, the variation in the characteristics among different articles concerning the severity and survival of COVID-19. Third, the small sample sizes of some studies besides most of the concerned articles were established within China, especially Wuhan. Finally, there was an observed publication bias and heterogeneity in this comprehensive meta-analysis.

Conclusion

494

495

496

497

498

499

500

501

502

503

505

506

In conclusion, several laboratory parameters could associate with the severity and mortality of COVID-19 infection and should be screened and measured continuously during the progression of this pandemic. These parameters included WBCs count, lymphocytes, platelet count, prothrombin time, D-dimer, and fibrinogen. Also, various interleukins could serve as anti-inflammatory markers such as IL-6, and IL-10 and should be evaluated. The estimation of other inflammatory biomarkers like CRP and procalcitonin could be helpful in the monitor the severity of the disease.

Acknowledgments

We thank all authors who provided published information for our meta-analysis.

Funding None

References

- Huang C, Wang Y, Li X, Ren L, Zhao J, Hu Y, et al. Clinical features of
- patients infected with 2019 novel coronavirus in Wuhan, China. Lancet.
- 509 2020; 395(10223): 497-506.
- 510 2. Rodriguez-Morales AJ, Cardona-Ospina JA, Gutiérrez-Ocampo E,
- Villamizar-Peña R, Holguin-Rivera Y, Escalera-Antezana JP, et al. Clinical,
- laboratory and imaging features of COVID-19: A systematic review and
- 513 meta-analysis. Travel medicine and infectious disease. 2020; 101623.
- 3. Al-Tawfiq JA, Gautret P. Asymptomatic Middle East Respiratory Syndrome

- Coronavirus (MERS-CoV) infection: Extent and implications for infection
- control: A systematic review. Travel Med Infect Dis, 2019; 27:27-32.
- 517 4. Ksiazek TG, Erdman D, Goldsmith CS, Zaki SR, Peret T, Emery S, et al. A
- novel coronavirus associated with severe acute respiratory syndrome. New
- England journal of medicine. 2003; 348(20):1953-66.
- 520 5. Rodriguez-Morales AJ, Bonilla-Aldana DK, Balbin-Ramon GJ, Rabaan AA,
- Sah R, Paniz-Mondolfi A, et al. History is repeating itself: Probable zoonotic
- spillover as the cause of the 2019 novel Coronavirus Epidemic. Infez Med.
- 523 2020; 28:3-5.
- 6. Chen N, Zhou M, Dong X, Qu J, Gong F, Han Y, et al. Epidemiological and
- clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in
- Wuhan, China: a descriptive study. The Lancet. 2020; 395:507-13.
- 7. Yin Y, Wunderink RG. MERS, SARS and other coronaviruses as causes of
- pneumonia. Respirology. 2018; 23:130-137.
- 529 8. Lechien JR, Chiesa Estomba CM, Place S, Van Laethem Y, Cabaraux P,
- Mat Q, et al. Clinical and Epidemiological Characteristics of 1,420 European
- Patients with mild to moderate Coronavirus Disease 2019. Journal of
- Internal Medicine. 2020.
- 533 9. Chen T, Wu D, Chen H, Yan W, Yang D, Chen G, et al. Clinical
- characteristics of 113 deceased patients with coronavirus disease 2019:
- retrospective study. Bmj. 2020; 368.
- 10. Udugama B, Kadhiresan P, Kozlowski HN, Malekjahani A, Osborne M, Li
- VY, et al. Diagnosing COVID-19: the disease and tools for detection. ACS
- 538 nano. 2020.
- 11. McInnes MD, Moher D, Thombs BD, McGrath TA, Bossuyt PM, Clifford
- T, et al. Preferred reporting items for a systematic review and meta-analysis
- of diagnostic test accuracy studies: the PRISMA-DTA statement. Jama.

- 542 2018; 319:388-396.
- 543 12. Kapadia MZ, Park CK, Beyene J, Giglia L, Maxwell C, McDonald SD.
- Weight loss instead of weight gain within the guidelines in obese women
- during pregnancy: a systematic review and meta-analyses of maternal and
- infant outcomes. PloS one. 2015; 10(7).
- 547 13. Stang A. Critical evaluation of the Newcastle-Ottawa scale for the
- assessment of the quality of nonrandomized studies in meta-analyses.
- European Journal of Epidemiology. 2010; 25: 603-605.
- 550 14. Wallace BC, Dahabreh IJ, Trikalinos TA, Lau J, Trow P, Schmid CH.
- Closing the gap between methodologists and end-users: R as a
- computational back-end. J Stat Softw. 2012; 49:1-5.
- 15. Pierce CA. Software Review: Borenstein, M, Hedges LV, Higgins JPT and
- Rothstein HR (2006). Comprehensive Meta-Analysis (Version 2.2.
- 555 027)[Computer software]. Englewood, NJ: Biostat. Organizational Research
- Methods. 2008; 11:188-191.
- 557 16. DerSimonian R, Laird N. Meta-analysis in clinical trials. Control Clin Trials.
- 558 1986; 7:177-188.
- 559 17. Andreano A, Rebora P, Valsecchi MG. Measures of single arm outcome in
- meta-analyses of rare events in the presence of competing risks. Biometrical
- Journal. 2015; 57: 649-660.
- 562 18. Elshazli RM, Toraih EA, Elgaml A, Kandil E, Fawzy MS. Genetic
- polymorphisms of TP53 (rs1042522) and MDM2 (rs2279744) and colorectal
- cancer risk: An updated meta-analysis based on 59 case-control studies.
- 565 Gene. 2020;144391.
- 19. Lin L, Chu H. Quantifying publication bias in meta-analysis. Biometrics.
- 567 2018; 74:785-794.
- 568 20. Duval S, Tweedie R, Nonparametric A. "Trim and Fill" Method of

- Accounting for Publication Bias in Meta-Analysis. Journal of the American
- 570 Statistical Association. 2000; 95:89-98.
- 571 21. Emami A, Javanmardi F, Pirbonyeh N, Akbari A. Prevalence of Underlying
- Diseases in Hospitalized Patients with COVID-19: a Systematic Review and
- 573 Meta-Analysis. Arch Acad Emerg Med. 2020; 8:e35.
- 574 22. Henry BM, De Oliveira MH, Benoit S, Plebani M, Lippi G. Hematologic,
- biochemical and immune biomarker abnormalities associated with severe
- illness and mortality in coronavirus disease 2019 (COVID-19): a meta-
- analysis. Clin Chem Lab Med. 2020.
- 578 23. Di Gennaro F, Pizzol D, Marotta C, Antunes M, Racalbuto V, Veronese N,
- et al. Coronavirus Diseases (COVID-19) Current Status and Future
- Perspectives: A Narrative Review. Int J Environ Res Public Health. 2020;
- 581 17.
- 582 24. Lippi G, Simundic AM, Plebani M. Potential preanalytical and analytical
- vulnerabilities in the laboratory diagnosis of coronavirus disease 2019
- (COVID-19). Clin Chem Lab Med. 2020.
- Lagier JC, Colson P, Dupont HT, Salomon J, Doudier B, Aubry C,, et al.,
- Testing the repatriated for SARS-Cov2: Should laboratory-based quarantine
- replace traditional quarantine? Travel Med Infect Dis. 2020; 101624.
- 588 26. Tan C, Huang Y, Shi F, Tan K, Ma Q, Chen Y, et al. C-reactive protein
- correlates with computed tomographic findings and predicts severe COVID-
- 19 early. J Med Virol. 2020.
- 591 27. He R, Lu Z, Zhang L, Fan T, Xiong R, Shen X, et al. The clinical course and
- its correlated immune status in COVID-19 pneumonia. Journal of Clinical
- 593 Virology. 2020; 104361.
- 594 28. Henry BM. COVID-19, ECMO, and lymphopenia: a word of caution.
- Lancet Respir Med. 2020; 8: e24.

- 596 29. Lippi G, Plebani M, Henry BM. Thrombocytopenia is associated with severe
- coronavirus disease 2019 (COVID-19) infections: A meta-analysis. Clinica
- 598 Chimica Acta. 2020; 506:145-148.
- 599 30. Shi Y, Wang Y, Shao C, Huang J, Gan J, Huang X, et al. COVID-19
- infection: the perspectives on immune responses. Cell Death Differ. 2020;
- 601 27: 1451-1454.
- 602 31. Tang N, Li D, Wang X, Sun Z. Abnormal coagulation parameters are
- associated with poor prognosis in patients with novel coronavirus
- pneumonia. Journal of Thrombosis and Haemostasis. 2020; 18:844-847.
- Ye Q, Wang B, Mao J. The pathogenesis and treatment of the `Cytokine
- Storm' in COVID-19. J Infect. 2020.
- 33. Zhao M. Cytokine storm and immunomodulatory therapy in COVID-19:
- Role of chloroquine and anti-IL-6 monoclonal antibodies. Int J Antimicrob
- Agents. 2020; 105982.
- 610 34. Lippi G, Plebani M. Procalcitonin in patients with severe coronavirus
- disease 2019 (COVID-19): A meta-analysis. Clin Chim Acta. 2020;
- 612 505:190-191.
- 513 35. Zhu Z, Cai T, Fan L, Lou K, Hua X, Huang Z,, et al. Clinical value of
- immune-inflammatory parameters to assess the severity of coronavirus
- disease 2019. International Journal of Infectious Diseases. 2020.
- 616 36. Liu X, Li Z, Liu S, Sun J, Chen Z, Jiang M, et al. Potential therapeutic
- effects of dipyridamole in the severely ill patients with COVID-19. Acta
- Pharm Sin B. 2020.
- 619 37. Chen X, Zhao B, Qu Y, Chen Y, Xiong J, Feng Y, et al. Detectable serum
- SARS-CoV-2 viral load (RNAaemia) is closely correlated with drastically
- elevated interleukin 6 (IL-6) level in critically ill COVID-19 patients. Clin
- Infect Dis. 2020.

- 623 38. Chen G, Wu D, Guo W, Cao Y, Huang D, Wang H, et al. Clinical and
- immunological features of severe and moderate coronavirus disease 2019. J
- 625 Clin Invest. 2020.
- 39. Zhang G, Hu C, Luo L, Fang F, Chen Y, Li J, et al. Clinical features and
- short-term outcomes of 221 patients with COVID-19 in Wuhan, China. J
- 628 Clin Virol. 2020; 127:104364.
- 629 40. Lei S, Jiang F, Su W, Chen C, Chen J, Mei W, et al. Clinical characteristics
- and outcomes of patients undergoing surgeries during the incubation period
- of COVID-19 infection. EClinicalMedicine. 2020; 100331.
- Wang L, He W, Yu X, Hu D, Bao M, Liu H, et al. Coronavirus disease 2019
- in elderly patients: Characteristics and prognostic factors based on 4-week
- follow-up. J Infect. 2020.
- 635 42. Guo T, Fan Y, Chen M, Wu X, Zhang L, He T, et al., Cardiovascular
- Implications of Fatal Outcomes of Patients With Coronavirus Disease 2019
- 637 (COVID-19). JAMA Cardiol. 2020.
- 638 43. Zheng C, Wang J, Guo H, Lu Z, Ma Y, Zhu Y, et al. Risk-adapted
- Treatment Strategy For COVID-19 Patients. Int J Infect Dis. 2020; 94: 74-
- 640 77.
- 44. Tang X, Du R, Wang R, Cao T, Guan L, Yang C et al. Comparison of
- Hospitalized Patients With ARDS Caused by COVID-19 and H1N1. Chest.
- 643 2020.
- 644 45. Shi S, Qin M, Shen B, Cai Y, Liu T, Yang F et al. Association of Cardiac
- Injury With Mortality in Hospitalized Patients With COVID-19 in Wuhan,
- China. JAMA Cardiol. 2020.
- 46. To KK, Tsang OT, Leung WS, Tam AR, Wu TC, Lung DC, et al. Temporal
- profiles of viral load in posterior or opharyngeal saliva samples and serum
- antibody responses during infection by SARS-CoV-2: an observational

- cohort study. Lancet Infect Dis. 2020.
- 47. Zhou Z, Guo D, Li C, Fang Z, Chen L, Yang R, et al. Coronavirus disease
- 2019: initial chest CT findings. Eur Radiol. 2020.
- 653 48. Chen Z, Fan H, Cai J, Li Y, Wu B, Hou Y, et al. High-resolution computed
- tomography manifestations of COVID-19 infections in patients of different
- ages. Eur J Radiol. 2020; 126:108972.
- Wan S, Xiang Y, Fang W, Zheng Y, Li B, Hu Y, et al. Clinical features and
- treatment of COVID-19 patients in northeast Chongqing. J Med Virol. 2020.
- 658 50. Cheng Y, Luo R, Wang K, Zhang M, Wang Z, Dong L, et al. Kidney
- disease is associated with in-hospital death of patients with COVID-19.
- Kidney Int. 2020.
- 51. Luo S, Zhang X, Xu H. Don't Overlook Digestive Symptoms in Patients
- With 2019 Novel Coronavirus Disease (COVID-19). Clin Gastroenterol
- 663 Hepatol. 2020.
- 52. Deng Y, Liu W, Liu K, Fang YY, Shang J, Wang K, et al. Clinical
- characteristics of fatal and recovered cases of coronavirus disease 2019
- 666 (COVID-19) in Wuhan, China: a retrospective study. Chin Med J (Engl).
- 667 2020.
- 668 53. Arentz M, Yim E, Klaff L, Lokhandwala S, Riedo FX, Chong M, et al.
- Characteristics and Outcomes of 21 Critically Ill Patients With COVID-19
- in Washington State. JAMA. 2020.
- 671 54. Chen J, Qi T, Liu L, Ling Y, Qian Z, Li T, et al. Clinical progression of
- patients with COVID-19 in Shanghai, China. J Infect. 2020; 80: e1-e6.
- 673 55. Cai Q, Yang M, Liu D, Chen J, Shu D, Xia J, et al., Experimental Treatment
- with Favipiravir for COVID-19: An Open-Label Control Study.
- Engineering. 2020.
- 676 56. Gao Y, Li T, Han M, Li X, Wu D, Xu Y, et al. Diagnostic utility of clinical

- laboratory data determinations for patients with the severe COVID-19. J
- 678 Med Virol. 2020.
- 679 57. Qian GQ, Yang NB, Ding F, Ma AH, Wang ZY, Shen YF, et al.
- Epidemiologic and Clinical Characteristics of 91 Hospitalized Patients with
- 681 COVID-19 in Zhejiang, China: A retrospective, multi-centre case series.
- 682 QJM. 2020.
- 58. Mo P, Xing Y, Xiao Y, Deng L, Zhao Q, Wang H, et al. Clinical
- characteristics of refractory COVID-19 pneumonia in Wuhan, China. Clin
- Infect Dis. 2020.
- 686 59. Cao J, Tu WJ, Cheng W, Yu L, Liu YK, Hu X, et al. Clinical Features of 69
- Cases with Coronavirus Disease 2019 in Wuhan, China. Clin Infect Dis.
- 688 2020.
- 689 60. Lo IL, Lio CF, Cheong HH, Lei CI, Cheong TH, Zhong X, et al. Evaluation
- of SARS-CoV-2 RNA shedding in clinical specimens and clinical
- characteristics of 10 patients with COVID-19 in Macau. Int J Biol Sci. 2020;
- 692 16:1698-1707.
- 61. Cheng Z, Lu Y, Cao Q, Qin L, Pan Z, Yan F, et al. Clinical Features and
- Chest CT Manifestations of Coronavirus Disease 2019 (COVID-19) in a
- Single-Center Study in Shanghai, China. AJR Am J Roentgenol. 2020; 1-6.
- 696 62. Hsih WH, Cheng MY, Ho MW, Chou CH, Lin PC, Chi CY, et al. Featuring
- 697 COVID-19 cases via screening symptomatic patients with epidemiologic
- link during flu season in a medical center of central Taiwan. Journal of
- Microbiology, Immunology and Infection. 2020.
- 700 63. Wu C, Chen X, Cai Y, Zhou X, Xu S, Huang H, et al. Risk Factors
- Associated With Acute Respiratory Distress Syndrome and Death in Patients
- With Coronavirus Disease 2019 Pneumonia in Wuhan, China. JAMA Intern
- 703 Med. 2020.

- 704 64. Qin C, Zhou L, Hu Z, Zhang S, Yang S, Tao Y, et al. Dysregulation of
- immune response in patients with COVID-19 in Wuhan, China. Clin Infect
- 706 Dis, 2020.
- 707 65. Zhao D, Yao F, Wang L, Zheng L, Gao Y, Ye J, et al., A comparative study
- on the clinical features of COVID-19 pneumonia to other pneumonias. Clin
- 709 Infect Dis. 2020.
- 710 66. Liu K, Chen Y, Lin R, Han K. Clinical features of COVID-19 in elderly
- patients: A comparison with young and middle-aged patients. J Infect, 2020.
- 712 67. Zhou, F., et al., Clinical course and risk factors for mortality of adult
- inpatients with COVID-19 in Wuhan, China: a retrospective cohort study.
- 714 Lancet. 2020; 395:1054-1062.
- 715 68. Xiong Y, Sun D, Liu Y, Fan Y, Zhao L, Li X, et al. Clinical and High-
- Resolution CT Features of the COVID-19 Infection: Comparison of the
- 717 Initial and Follow-up Changes. Invest Radiol. 2020.
- 718 69. Fan BE, Chong VC, Chan SS, Lim GH, Lim KG, Tan GB, et al.,
- Hematologic parameters in patients with COVID-19 infection. Am J
- 720 Hematol. 2020.
- 721 70. Young BE, Ong SW, Kalimuddin S, Low JG, Tan SY, Loh J, et al.
- Epidemiologic Features and Clinical Course of Patients Infected With
- SARS-CoV-2 in Singapore. JAMA. 2020.
- 724 71. Wu J, Liu J, Zhao X, Liu C, Wang W, Wang D, et al. Clinical
- Characteristics of Imported Cases of COVID-19 in Jiangsu Province: A
- Multicenter Descriptive Study. Clin Infect Dis. 2020.
- 727 72. Li K, Wu J, Wu F, Guo D, Chen L, Fang Z, et al. The Clinical and Chest CT
- Features Associated with Severe and Critical COVID-19 Pneumonia. Invest
- 729 Radiol. 2020.
- 73. Liu W, Tao ZW, Wang L, Yuan ML, Liu K, Zhou L, et al. Analysis of

- factors associated with disease outcomes in hospitalized patients with 2019
- novel coronavirus disease. Chin Med J (Engl). 2020.
- 733 74. Yang W, Cao Q, Qin L, Wang X, Cheng Z, Pan A, et al. Clinical
- characteristics and imaging manifestations of the 2019 novel coronavirus
- disease (COVID-19):A multi-center study in Wenzhou city, Zhejiang,
- 736 China. J Infect. 2020; 80: 388-393.
- 737 75. Wu J, Wu X, Zeng W, Guo D, Fang Z, Chen L, et al. Chest CT Findings in
- Patients With Coronavirus Disease 2019 and Its Relationship With Clinical
- Features. Invest Radiol. 2020; 55:257-261.
- 740 76. Shi H, Han X, Jiang N, Cao Y, Alwalid O, Gu J, et al. Radiological findings
- from 81 patients with COVID-19 pneumonia in Wuhan, China: a descriptive
- study. Lancet Infect Dis. 2020.
- 743 77. Yang X, Yu Y, Xu J, Shu H, Liu H, Wu Y, et al. Clinical course and
- outcomes of critically ill patients with SARS-CoV-2 pneumonia in Wuhan,
- China: a single-centered, retrospective, observational study. Lancet Respir
- 746 Med. 2020.
- 747 78. Zhang JJ, Dong X, Cao YY, Yuan YD, Yang YB, Yan YQ, et al. Clinical
- characteristics of 140 patients infected with SARS-CoV-2 in Wuhan, China.
- 749 Allergy. 2020.
- 750 79. Zhou W, Liu Y, Tian D, Wang C, Wang S, Cheng J, et al. Potential benefits
- of precise corticosteroids therapy for severe 2019-nCoV pneumonia. Signal
- Transduction and Targeted Therapy. 2020; 5(1).
- 753 80. Xu XW, Wu XX, Jiang XG, Xu KJ, Ying LJ, Ma CL, et al. Clinical findings
- in a group of patients infected with the 2019 novel coronavirus (SARS-Cov-
- 2) outside of Wuhan, China: retrospective case series. BMJ. 2020; 368:
- m606.
- 757 81. Pan F, Ye T, Sun P, Gui S, Liang B, Li L, et al. Time Course of Lung

- Changes On Chest CT During Recovery From 2019 Novel Coronavirus (COVID-19) Pneumonia. Radiology. 2020; 200370.
- 760 82. Chang D, Lin M, Wei L, Xie L, Zhu G, Cruz CS, et al. Epidemiologic and
 761 Clinical Characteristics of Novel Coronavirus Infections Involving 13
 762 Patients Outside Wuhan, China. JAMA. 2020; 323:1092-1093.
- 763 83. Wang D, Hu B, Hu C, Zhu F, Liu X, Zhang J, et al. Clinical Characteristics 764 of 138 Hospitalized Patients With 2019 Novel Coronavirus–Infected 765 Pneumonia in Wuhan, China. JAMA. 2020; 323: 1061-1069.

Supporting Materials:

- Table S1 PRISMA Checklist.
- Fig S1 Publication bias
- Funnel plot of standard error by the standardized difference in means for (A) White 767 blood cells, (B) Neutrophil count, (C) Lymphocyte count, (D) Procalcitonin, and 768 (E) C-reactive protein. The standard error provides a measure of the precision of 769 the effect size as an estimate of the population parameter. It starts with zero at the 770 771 top. Studies with smaller sample sizes produce less precise estimated effects with a broader base. The pooled estimated effects would be expected to scatter 772 symmetrically around the total overall estimate of the meta-analysis (represented 773 by the vertical line). Each circle represents a study (black circle). In the case of 774 asymmetry, Duval and Tweedie's trim and fill method predict the missing studies 775 776 (red circle). Begg's and Egger's tests were performed. P values <0.1 were set to have a significant bias. 777



